Cargando…

Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer

BACKGROUND: The reported penetrance of germline CDH1 mutations is high in families with hereditary diffuse gastric cancer (HDGC). Men and women have a 70% and 56%, respectively, cumulative risk of developing diffuse gastric cancer by age 80. Women additionally have a 42% cumulative risk of developin...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Julie M., Laukaitis, Christina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799867/
https://www.ncbi.nlm.nih.gov/pubmed/27064202
http://dx.doi.org/10.1002/mgg3.197
_version_ 1782422409865854976
author Huynh, Julie M.
Laukaitis, Christina M.
author_facet Huynh, Julie M.
Laukaitis, Christina M.
author_sort Huynh, Julie M.
collection PubMed
description BACKGROUND: The reported penetrance of germline CDH1 mutations is high in families with hereditary diffuse gastric cancer (HDGC). Men and women have a 70% and 56%, respectively, cumulative risk of developing diffuse gastric cancer by age 80. Women additionally have a 42% cumulative risk of developing breast cancer. Due to the high penetrance of these mutations, prophylactic total gastrectomy is currently recommended for CDH1 mutation carriers. However, whether everyone with a CDH1 gene mutation is at risk for HDGC is not clear. METHODS: Mutation identification was performed by next‐generation sequencing. Mutations and variant status was confirmed by Sanger sequencing in 11 family members. RESULTS: We present two families with pathogenic CDH1 mutations. The first family carries a novel truncating, nonsense CDH1 mutation that we were able to trace for three generations, but reports no family history of diffuse gastric cancer. The occurrence of cancer in this family deviates significantly from the expectation for HDGC. The proband from the second family presents with breast cancer and carries a previously reported pathogenic CDH1 mutation, but also reports no family history of diffuse gastric cancer. CONCLUSIONS: Our study demonstrates the need for further analysis of CDH1 mutation penetrance in order to better counsel asymptomatic CDH1 mutation carriers on preventative measures and general care.
format Online
Article
Text
id pubmed-4799867
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-47998672016-04-08 Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer Huynh, Julie M. Laukaitis, Christina M. Mol Genet Genomic Med Clinical Report BACKGROUND: The reported penetrance of germline CDH1 mutations is high in families with hereditary diffuse gastric cancer (HDGC). Men and women have a 70% and 56%, respectively, cumulative risk of developing diffuse gastric cancer by age 80. Women additionally have a 42% cumulative risk of developing breast cancer. Due to the high penetrance of these mutations, prophylactic total gastrectomy is currently recommended for CDH1 mutation carriers. However, whether everyone with a CDH1 gene mutation is at risk for HDGC is not clear. METHODS: Mutation identification was performed by next‐generation sequencing. Mutations and variant status was confirmed by Sanger sequencing in 11 family members. RESULTS: We present two families with pathogenic CDH1 mutations. The first family carries a novel truncating, nonsense CDH1 mutation that we were able to trace for three generations, but reports no family history of diffuse gastric cancer. The occurrence of cancer in this family deviates significantly from the expectation for HDGC. The proband from the second family presents with breast cancer and carries a previously reported pathogenic CDH1 mutation, but also reports no family history of diffuse gastric cancer. CONCLUSIONS: Our study demonstrates the need for further analysis of CDH1 mutation penetrance in order to better counsel asymptomatic CDH1 mutation carriers on preventative measures and general care. John Wiley and Sons Inc. 2016-01-13 /pmc/articles/PMC4799867/ /pubmed/27064202 http://dx.doi.org/10.1002/mgg3.197 Text en © 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Report
Huynh, Julie M.
Laukaitis, Christina M.
Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer
title Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer
title_full Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer
title_fullStr Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer
title_full_unstemmed Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer
title_short Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer
title_sort panel testing reveals nonsense and missense cdh1 mutations in families without hereditary diffuse gastric cancer
topic Clinical Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799867/
https://www.ncbi.nlm.nih.gov/pubmed/27064202
http://dx.doi.org/10.1002/mgg3.197
work_keys_str_mv AT huynhjuliem paneltestingrevealsnonsenseandmissensecdh1mutationsinfamilieswithouthereditarydiffusegastriccancer
AT laukaitischristinam paneltestingrevealsnonsenseandmissensecdh1mutationsinfamilieswithouthereditarydiffusegastriccancer